While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

Broadcom is near a buy point while CrowdStrike and HubSpot offer early entries. Watch out for earnings from group peers and ...